The antiangiogenic compound axitinib demonstrates low toxicity and anti-tumoral effects against medulloblastoma
M. Pagnuzzi-Boncompagni, V. Picco, V. Vial, V. Planas-Bielsa, A. Vandenberghe, R. Grepin, J. Durivault, C. Montemagno, S. Martial, J. Doyen, J. Gavard, G. Pages
This study evaluates axitinib's efficacy and safety in medulloblastoma, finding it has low toxicity and anti-tumoral effects in preclinical models and poor prognosis association in public databases.
bioRxiv · Sep 18, 2020 · PreprintCancer Biology